CEA（癌胚抗原）市场规模、份额、成长分析（按测试类型、最终用途）- 产业预测，2024-2031 年

Carcinoembryonic Antigen Market Size, Share, Growth Analysis, By Test type(Molecular Tests, Serology Tests), By Application(Colorectal Cancer, Pancreatic Cancer), By End use industry(Hospitals, Laboratories) - Industry Forecast 2024-2031

出版日期: 2024年06月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年CEA（癌胚抗原）的全球市场规模为18.3亿美元，在预测期内从2023年的19.8亿美元成长到2031年的26.3亿美元（预计复合年增长率为4.1%） 2024 年至2031年）。

考虑到健康危机的经济影响，CD66a将在2021年占据CEA（癌胚抗原）全球市场的一部分，并以修正后的复合年增长率增长，预计到2028年将达到百万美元的价值。相反，大肠直肠癌成为2021年的首要应用领域，市场占有率超过%。在预测期内，市场占有率预计将成长%。在预测期内，饮酒增加和久坐的生活方式等因素可能在大肠癌的增加中发挥更大的作用。根据参与者、类型、区域（国家）和应用对全球癌胚抗原市场进行分析。本报告重点关注2017年至2028年的收益预测，按地区（国家）、类型和应用进行细分。它重点关注 2017 年至 2028 年美国市场按公司、类型和应用分類的 CEA（癌胚抗原）市场规模。全球和本地公司是美国行业的重要参与者，也是该市场考虑的主要参与者之一。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

F. Hoffmann-La Roche Ltd.（Switzerland）
Boster Biological Technology（US）
RayBiotech, Inc.（US）
Correlogic Systems, Inc.（US）
Quest Diagnostics（US）
Omega Diagnostics Group PLC（UK）
GenWay Biotech Inc.（US）
Abbot（US）
Creative Diagnostics（US）

简介目录

Product Code: SQMIG35H2233

Global Carcinoembryonic Antigen Market size was valued at USD 1.83 billion in 2022 and is poised to grow from USD 1.98 billion in 2023 to USD 2.63 billion by 2031, growing at a CAGR of 4.1% during the forecast period (2024-2031).

In light of the health crisis's impact on the economy, CD66a is predicted to hold a portion of the global market for carcinoembryonic antigen (CEA) in 2021 and increase at a revised percent compound annual growth rate (CAGR) to reach a value of USD million by 2028. Conversely, Colorectal Cancer emerged as the top application segment in 2021, with a market share exceeding %. It is anticipated to grow at a rate of % over the course of the forecast period. During the projected period, factors including rising alcohol use and sedentary lifestyles are probably going to have a bigger role in the increase of colorectal cancer. Analysis of the global market for carcinoembryonic antigen (CEA) is done based on players, types, regions (countries), and applications. The report's main focus is on revenue projections for the years 2017-2028, broken down by area (country), kind, and application. The study focuses on the Carcinoembryonic Antigen (CEA) market size, by companies, type, and application, for the US market from 2017 to 2028. Global and local firms that are significant players in the US industry are among the main players taken into consideration in this market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Carcinoembryonic Antigen Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Carcinoembryonic Antigen Market Segmental Analysis

The global carcinoembryonic antigen market is segmented based on test type, application, end use industry, and region. Based on test type, the market is segmented into Molecular Tests, and Serology Tests. Based on application, the market is segmented into Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Thyroid Cancer, Others. Based on end use industry, the market is segmented into Hospitals, Laboratories, and Others. Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Carcinoembryonic Antigen Market

Global cancer patient numbers have been rising rapidly, raising serious concerns about the health of the world's population. Cancer is the second greatest cause of mortality worldwide, with 70% of cancer-related fatalities happening in rural regions. The market for cancer diagnostics is expanding as a result of the rising prevalence of cancer, which has raised demand for diagnostic procedures-including minimally invasive ones-and raised per capita healthcare spending.

Restraints in the Global Carcinoembryonic Antigen Market

Certain obstacles impede the expansion of the carcinoembryonic antigen (CEA) market. These comprise the underutilization of CEA testing, the inability to identify cancer in its early stages, and the possible infection risk connected to CEA testing.

Market Trends of the Global Carcinoembryonic Antigen Market

Early cancer identification is becoming more and more important since it increases patient survival rates and treatment outcomes. When it comes to the early identification and tracking of specific cancer types, CEA testing is crucial. Consequently, there is an increasing need for CEA testing as part of standard cancer screening protocols and cancer patient monitoring.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Pricing Analysis
Start Up Analysis
Regulatory Landscape
Patent Analysis
Pipeline Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Carcinoembryonic Antigen Market by Application

Market Overview
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
Others

Carcinoembryonic Antigen Market by End Use Industry

Market Overview
Hospital
Laboratories
Others

Carcinoembryonic Antigen Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boster Biological Technology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RayBiotech, Inc.(US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Correlogic Systems, Inc.(US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omega Diagnostics Group PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenWay Biotech Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbot (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments